Faeth Therapeutics reported preliminary Phase 2 clinical results evaluating PIKTOR in advanced endometrioid endometrial cancer. In the ongoing PIK-201 trial, the combination of PIKTOR and paclitaxel demonstrated a confirmed objective response rate of 33% across 36 evaluable patients.
Faeth Chief Executive Anand Parikh stated: "Targeting multiple components of the PI3K and mTOR pathways could provide a vital treatment approach for advanced endometrial cancer."
The study achieved a disease control rate of 83% and a preliminary median progression-free survival of 7.4 months among heavily pretreated individuals.
PIKTOR is engineered as an oral targeted agent designed to overcome chemotherapy resistance by selectively suppressing cancer cell metabolic signaling. Clinical investigators reported manageable safety profiles without unexpected dose-limiting toxicities during the multi-center evaluation.
